亚洲美腿欧美激情另类,国产美女直播视频一区,亚洲手机视频

產(chǎn)品詳情

查看大圖

產(chǎn)品名稱：NIHOVCAR-3 人卵巢癌細(xì)胞
產(chǎn)品型號(hào)：HTB-161
產(chǎn)品廠商：美國標(biāo)準(zhǔn)生物品收藏中心（ATCC）
產(chǎn)品價(jià)格：0
折扣價(jià)格：0
產(chǎn)品文檔：

你添加了1件商品查看購物車

簡單介紹：

HTB-161 NIH：OVCAR-3 人卵巢癌細(xì)胞，原代細(xì)胞|細(xì)胞系|細(xì)胞株|菌種；細(xì)胞庫管理規(guī)范，提供的細(xì)胞株背景清楚，提供參考文獻(xiàn)和培養(yǎng)條件！

詳情介紹：

HTB-161 NIH：OVCAR-3 人卵巢癌細(xì)胞

ATCC^® Number:

HTB-161?

Price:

$272.00

Designations:	NIH:OVCAR-3
Depositors:	R Ozols, TC Hamilton
Biosafety Level:	1
Shipped:	frozen
Medium & Serum:	See Propagation
Growth Properties:	adherent
Organism:	Homo sapiens (human)
Morphology:	epithelial
Source:	Organ: ovary Disease: adenocarcinoma Cell Type: epithelial
Permits/Forms:	In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.

Isolation:	Isolation date: 1982
Applications:	transfection host (Roche FuGENE® Transfection Reagents)
Receptors:	androgen receptor, positive; estrogen receptor, positive; progesterone receptor, positive
Tumorigenic:	Yes
DNA Profile (STR):	Amelogenin: X CSF1PO: 11,12 D13S317: 12 D16S539: 12 D5S818: 11,12 D7S820: 10 THO1: 9,9.3 TPOX: 8 vWA: 17
Cytogenetic Analysis:	The cell line is aneuploid human female, with chromosome counts in the sub to near-triploid range. Several normal chromosomes (N11, N13, N14, N15, N16, N17, and N22) are clearly under-represented. Many of these missing chromosomes are represented in the large number of cytogenetically altered chromosomes identified as marker chromosomes. In addition to the marker chromosomes, there are a large number of other structurally abnormal and unassignable chromosomes that are not recognized as markers. Random loss and gain of chromosomes from cell to cell are noted in the exact chromosome counts and in the analysis of the karyotypes.
Isoenzymes:	AK-1, 1 ES-D, 1 G6PD, B GLO-I, 1 PGM1, 1 PGM3, 1
Age:	60 years
Gender:	female
Ethnicity:	Caucasian
Comments:	The NIH:OVCAR-3 line was established in 1982 by T.C. Hamilton, et al. from the malignant ascites of a patient with progressive adenocarcinoma of the ovary. Forms colonies in soft agar and has an abnormal karyotype. Resistant to clinically relevant concentrations of adriamycin, melphalan and cisplatin. Both cultured cells and xenografts exhibit androgen and estrogen receptors. Xenograft models have been used to show that treatment with 17 beta estradiol can induce progesterone receptors in this human ovarian carcinoma. NIH:OVCAR-3 is an appropriate model system in which to study drug resistance in ovarian cancer, and the presence of hormone receptors should be useful for the evaluation of hormonal therapy.
Propagation:	ATCC complete growth medium: The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: 0.01 mg/ml bovine insulin; fetal bovine serum to a final concentration of 20%. Temperature: 37.0°C Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Subculturing:	Protocol: Remove medium, and rinse with 0.25% trypsin, 0.53 mM EDTA solution. Remove the solution and add an additional 1 to 2 ml of trypsin-EDTA solution. Allow the flask to sit at room temperature (or at 37C) until the cells detach. Add fresh culture medium, aspirate and dispense into new culture flasks. Subcultivation Ratio: A subcultivation ratio of 1:2 to 1:4 is recommended Medium Renewal: Every 2 to 3 days
Preservation:	Freeze medium: Complete growth medium, 95%; DMSO, 5% Storage temperature: liquid nitrogen vapor temperature
Related Products:	Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2001 recommended serum:ATCC 30-2020
References:	1127: Hamilton TC, et al. Characterization of a human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and estrogen receptors. Cancer Res. 43: 5379-5389, 1983. PubMed: 6604576 1128: Hamilton TC, et al. Induction of progesterone receptor with 17beta-estradiol in human ovarian cancer. J. Clin. Endocrinol. Metab. 59: 561-563, 1984. PubMed: 6746867 22949: Rogan AM, et al. Reversal of adriamycin resistance by verapamil in human ovarian cancer. Science 224: 994-996, 1984. PubMed: 6372095 23051: Hamilton TC, et al. Characterization of a xenograft model of human ovarian carcinoma which produces ascites and intraabdominal carcinomatosis in mice. Cancer Res. 44: 5286-5290, 1984. PubMed: 6333272 23052: Green JA, et al. Potentiation of melphalan cytotoxicity in human ovarian cancer cell lines by glutathione depletion. Cancer Res. 44: 5427-5431, 1984. PubMed: 6488194 23100: Caffrey PB, Frenkel GD. Selenite cytotoxicity in drug resistant and nonresistant human ovarian tumor cells. Cancer Res. 52: 4812-4816, 1992. PubMed: 1511444 23164: Hamilton TC, et al. Experimental model systems of ovarian cancer: applications to the design and evaluation of new treatment approaches. Semin. Oncol. 11: 285-298, 1984. PubMed: 6385258 23329: Godwin AK, et al. High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc. Natl. Acad. Sci. USA 89: 3070-3074, 1992. PubMed: 1348364 32582: Chang K, Pastan I. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc. Natl. Acad. Sci. USA 93: 136-140, 1996. PubMed: 8552591 32690: Omelyanenko V, et al. HPMA copolymer-anticancer drug-OV-TL16 antibody conjugates. II. Processing in epithelial ovarian carcinoma cells in vitro. Int. J. Cancer 75: 600-608, 1998. PubMed: 9466663

姓名：

電話：

Email：

您的需求：

滬公網(wǎng)安備 31010902002429號(hào)

產(chǎn)品名稱：NIHOVCAR-3 人卵巢癌細(xì)胞